The University of Texas System

Isis Pharmaceuticals, Inc.

Stanislaw M Stepkowski

Barry D Kahan

Waldemar Priebe

Izabela Fokt

Szymon Kosinski

Robert A Kirken

C Frank Bennett

Rafik R Ghobrial

Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.

Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3)

Chimeric MHC Class I molecules having a recipient-type N-terminus, a donor-type alpha-1 helical region, and a recipient-type alpha-2 domain induce tolerance to donor grafts when administered to the recipient at time of transplantation.

Chimeric MHC class I antigens for inducing allograft tolerance

Compositions and methods are provided for the prevention and treatment of allograft rejection. Compositions are provided which comprise an antisense oligonucleotide targeted to a nucleic acid sequence encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, or endothelial leukocyte adhesion molecule-1 in combination with an immunosuppressive agent. Methods of preventing or treating allograft rejection by treating an allograft recipient with such a composition are provided. Methods for preventing allograft rejection comprising perfusion of the graft are also provided.

Compositions and methods for preventing and treating allograft rejection

Growing community of inventors

Pearland, TX, United States of America

Stanislaw M Stepkowski